The adaptogen for stress & resilience
Ashwagandha (Withania somnifera) is a powerful adaptogenic herb that has been used for thousands of years in traditional Ayurvedic medicine. It is classified as an adaptogen, meaning it may help the body manage stress and maintain balance.
Modern research has focused on its ability to support healthy cortisol levels, reduce feelings of stress, and promote better sleep quality. It is one of the most studied adaptogens available today.
Ashwagandha supplements sold in the United States and most Western markets use root extracts — and this is correct. The root is where centuries of Ayurvedic tradition, all major clinical trials, and the most studied branded extracts (KSM-66, Sensoril) are grounded. But not every label makes this explicit, and a small number of products use leaf material or undisclosed "whole plant" blends. Here's why the difference matters.
Withanolides are the primary bioactive compounds in ashwagandha — they drive the adaptogenic effects. But not all withanolides are equal. Withaferin-A is a particularly potent steroidal lactone that has attracted significant research interest for its anti-inflammatory and cytotoxic (cell-killing) properties in lab and animal studies, including possible anti-cancer mechanisms.
The problem: Withaferin-A's potency that makes it interesting for cancer research also raises safety questions for daily oral supplementation at the doses found in leaf-based products. Preclinical data has flagged potential hepatotoxic (liver-damaging) signals at higher exposures. This is the core scientific reason the 2024 AYUSH expert committee recommended root-only restrictions — leaves contain 8–22× more Withaferin-A than roots.
In roots, Withaferin-A is present at low concentrations alongside other withanolides (including the safer withanosides) in a profile consistent with traditional use and clinical trial safety data. In leaves, that balance is shifted.
India's Food Safety and Standards Authority, in coordination with the Ministry of AYUSH, issued a regulatory clarification in April 2026: only dried mature roots and root extracts of Withania somnifera are permitted in health supplements and nutraceuticals. Leaf material in any form — crude, extract, or blend — is not permitted. This is not a new ban on ashwagandha; it is a root-only clarification targeting manufacturers who had been using leaves. Manufacturers are now required to declare the plant part on labels.
Denmark's 2023 ban on ashwagandha is separate and more controversial — it applies broadly to root extracts, the same material sold everywhere else. It stems from a 2020 DTU risk assessment citing possible effects on sex hormones, thyroid function, and metabolism under the precautionary principle. The scientific community has widely criticized this as overly restrictive given the extensive human clinical trial data at typical doses (300–600mg/day). No other Western country has followed Denmark's lead. The US, UK, EU, Canada, and Australia all continue to permit ashwagandha root extracts.
Research suggests ashwagandha may support healthy stress response and help maintain normal cortisol levels, especially during periods of high stress.
May help improve sleep quality and reduce time to fall asleep in people experiencing stress-related sleep issues.
Some studies show benefits for overall sense of well-being and emotional resilience when used consistently over 6–8 weeks.
Most people tolerate ashwagandha well when taken at recommended doses. Side effects are generally mild and uncommon.
Hundreds of clinical trials and meta-analyses support ashwagandha root extract for stress reduction, cortisol lowering, and sleep quality. A well-cited 2012 study (Chandrasekhar et al.) demonstrated significant reduction in serum cortisol and self-reported stress scores at 300mg KSM-66 twice daily over 60 days. A 2014 systematic review (Pratte et al.) confirmed benefits across multiple stress and anxiety measures. Safety data from these root-only trials is consistently favourable at standard doses.
It’s worth noting: the 2024 AYUSH safety dossier reviewed all available clinical data and concluded that root extracts have a well-established safety and efficacy profile — and that the leaf-restriction is a precautionary measure based on phytochemical differences, not a response to reported adverse events from root supplementation at normal doses.
| Ingredient | Best For | Key Difference |
|---|---|---|
| Ashwagandha | Stress, Cortisol, Sleep | Works on HPA axis; effects build over weeks |
| Rhodiola Rosea | Mental fatigue, Focus | Faster acting; more stimulating |
| L-Theanine | Calm focus, Relaxation | Works quickly (within 30–60 min) |
Many people stack ashwagandha with magnesium or L-theanine for enhanced effects.
Full stack recommendations coming soon in our Stacks section.
1. Chandrasekhar K et al. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine, 34(3), 255–262.
2. Pratte MA et al. (2014). An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). Journal of Alternative and Complementary Medicine, 20(12), 901–908.
3. Langade D et al. (2019). Efficacy and safety of ashwagandha (Withania somnifera) root extract in insomnia and anxiety: a double-blind, randomized, placebo-controlled study. Cureus, 11(9), e5797.
All references are peer-reviewed studies or position stands from reputable organizations.